Matthew A. Spear, M.D.

Chief Medical Officer

Dr. Spear joined Poseida as Chief Medical Officer in June of 2016. From April 2016 until July 2016, Dr. Spear served as head of Clinical Development and Vice President at Sangamo Biosciences Inc. From 2014 to 2016, Dr. Spear was Vice President, Clinical Development and Translational Medicine at Incyte Corporation, a research company specializing in oncology product development and innovative medicines. Dr. Spear served as head of oncology and head of biotherapeutics at Sunovion Pharmaceuticals, Inc. from January 2012 to July 2014. From 2005 to 2011, Dr. Spear held several roles at Nereus Pharmaceuticals, Inc., most recently he served as Chief Medical Officer. Prior to joining Nereus, Dr. Spear led multiple oncology clinical development programs at Pfizer as an associate professor at the Keck School of Medicine of USC, and the UCSD School of Medicine and UCSD Cancer Center. He has also served on NIH/NCI study section, biotechnology and pharmaceutical advisory boards, IRB/SRC and scientific journal editorial review committees related to cancer, as well as authoring numerous scientific papers and patents. His residency and fellowship was conducted in the Massachusetts General Hospital/Harvard University program. Dr. Spear received his M.D. from Stanford University Medical School and his B.S. and B.A. in biology from Johns Hopkins University.